We found no significant relationship between fatty replacement and disease duration in anti‐TIF1‐γ‐positive DM in our analysis, which differed from sporadic inclusion body myositis (sIBM) and anti‐SRP myopathy. This evidence concerns the gene TRIM33 and dermatomyositis.